key: cord-1026876-x4zuv4jo authors: Zeng, Qing-Lei; Yu, Zu-Jiang; Gou, Jian-Jun; Li, Guang-Ming; Ma, Shu-Huan; Zhang, Guo-Fan; Xu, Jiang-Hai; Lin, Wan-Bao; Cui, Guang-Lin; Zhang, Min-Min; Li, Cheng; Wang, Ze-Shuai; Zhang, Zhi-Hao; Liu, Zhang-Suo title: Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients date: 2020-04-29 journal: J Infect Dis DOI: 10.1093/infdis/jiaa228 sha: c5b56e5c1e33dcf247157b735550f7d8da7a0e5c doc_id: 1026876 cord_uid: x4zuv4jo Currently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) has been reported in almost all countries globally, and no effective therapy has been documented for COVID-19 and the role of convalescent plasma therapy is unknown. In current study, 6 COVID-19 subjects with respiratory failure received convalescent plasma at a median of 21.5 days after first detection of viral shedding, all tested negative for SARS-CoV-2 RNA by 3 days after infusion, and 5 died eventually. In conclusion, convalescent plasma treatment can discontinue SARS-CoV-2 shedding but cannot reduce mortality in critically end-stage COVID-19 patients, and treatment should be initiated earlier. The technical performances of aforementioned detection kit are as following. (1) Limit of detection: 1×10 3 copies/ml. (2) Repeatability: A reference sample with the same precision was tested in five days by two persons with three batches of reagents, and the coefficient of variation of the intra-batch and inter-batch precision, intra-day and inter-day precision, intra-operator and inter-operator precision, and intra-laboratory and inter-laboratory precision is no more than 5.0% in all instances. (3) Positive/negative reference compliance rate within the company: The compliance rate is 100% for five positive reference samples and 12 negative reference samples. ( Convalescent plasma was obtained from individuals who had recovered from COVID-19. Young adult individuals who recovered from COVID-19 for one week to two weeks were eligible for further estimations as the blood donors. Additionally, all the donors were negative for the testing of SARS-CoV-2 RNA and IgM, and positive for IgG testing before donations. Informed consent was obtained from all donors who should be seronegative for hepatitis B and C, human immunodeficiency virus, and syphilis. From the mid-February, 2020, first recovered COVID-19 individual has donated the blood sample. A 200 to 400 ml plasma sample was harvested from each donor, the blood collection and storage process were performed in Henan (Provincial) Red Cross Blood Center. Gold immnnochromatography for SARS-CoV-2 IgM and IgG tests were performed using blood sample Continuous and categorical variables were presented as median (interquartile range) and n (%), respectively. Mann-Whitney U test, Chi-square test, or Fisher's exact test were used to compare the differences between various subgroups where appropriate. Analyses were carried out using SPSS statistical software, version 25.0 (IBM, Chicago, IL, USA). A p value of < 0.05 was set as the threshold for statistical significance. The protocol of this retrospective study was approved by the Institutional Review Board of The First Affiliated Hospital of Zhengzhou University, and the written informed consents were obtained from all the family members of patients who received plasma infusions. A total of 21 contemporaneously critical COVID-19 patients were enrolled in current study (Table 1) , all patients required intensive care unit admission. Of them, 6 patients received convalescent plasma treatment based on the limited convalescent plasma availability and ABO compatibility. There are 5 and 11 male patients in convalescent plasma treatment group and non-convalescent plasma treatment (control) group, respectively. The median ages were 61.5 and 73 years respectively. The treatment group and control group had the comparable characteristics, clinical parameters, and management strategies ( Table 1) . A c c e p t e d M a n u s c r i p t 8 The median volume of plasma infused was 300 ml (Table 2) . No immediate and noticeable adverse effects were observed with convalescent plasma infusions. The mortality in the treatment group was 5/6 and in the control group was 14/15 (p = 0.184). Each group had one recovered patient, respectively. All the 6 patients in treatment group obtained viral clearance after convalescent plasma transfusions, and 100% (5/5) and 21.4% (3/14) of fatal patients had undetectable SARS-CoV-2 before death in treatment and control groups, respectively (p = 0.005). Additionally, the survival period of treatment group was longer than control group (p = 0.029). In Henan Province, the first available convalescent plasma was transfused for a 30 years postpartum woman on February 19, 2020 (Supplementary Figure 1) . She was engaged in beef and mutton selling business in Wuhan and came to Henan Province at 29 gestational weeks plus 3 days on January 21, 2020, and initiated the illness with fever and dry cough on January 24. Then, she visited the hospital for testing and management, her SARS-CoV-2 was first detectable from January 28. On February 2, she had the caesarean section because of fetal destress, fortunately, the premature newborn was living and negative for SARS-CoV-2 for one month after birth. Recent study indicated that SARS-CoV-2 was detectable until death in non-survivors [14] , and whether undetectable SARS-CoV-2 before death can regress fatalities is unknown. In current study, to the best of our knowledge, we firstly indicate that the convalescent plasma treatment contributes to the discontinuation of SARS-CoV-2 shedding and longer survival duration in COVID-19 patients with respiratory failure; however, it cannot reduce the mortality in critically end-stage COVID-19 patients. As the neighbor Province of Hubei and nearest outside Province of Wuhan City, Henan Province was affected by the SARS-CoV-2 infection severely. It is known that Henan Province had the third largest number of COVID-19 patients and second largest number of fatal patients in China [15] . However, in mid-February, 2020, the epidemic was closing to the end, therefore, the enrolled patients were the most critical and last series of COVID-19 cases in Henan Province. Commonly, viraemia peaks in the first week after infection in most acute viral diseases, and patient usually develops a primary immune response by day 10 to 14, which is followed by virus clearance [8] . In the third week, and clinical deterioration is occurred to be the result of inflammatory or hyperimmune attacks rather than direct viral-induced tissue damage [8, 14, 16] . Hence, convalescent plasma should theoretically be more effective when given in the early course of disease (i.e., before day 14, or during the viremic and seronegative stage) [8] . The failure of reduce the mortality may be attributed to the late transfusion of convalescent plasma, which were given on median day 21.5 during viral shedding. On the contrary, one critical patient in treatment group infused on day 11 during viral shedding was finally recovered. Based on the current findings, the convalescent plasma treatment should be given to the COVD-19 patients with right phase or severity at the right timepoint. It is known that most mild COVD-19 patients can be self-recovered, and convalescent plasma may be improper therapy for them. And for end-stage COVD-19 patients, the convalescent plasma treatment may unable to regress the poor outcome as demonstrated by current study. Hence, the convalescent plasma treatment should probably A c c e p t e d M a n u s c r i p t 10 be used in potentially critical COVD-19 patients at their early stage. Thus, the early recognition of the COVD-19 patients who would subsequently and potentially develop to critically illness is the key question before the convalescent plasma treatment. Our study has several limitations. First, limited number of patients. It is important to note that the COVID-19 outbreak was nearly finished outside Wuhan in China at the convalescent plasma available date, i.e., February 19 in Henan Province. Then, the vast majority of patients were discharged and new cases were few, and these 21 patients were almost all the critically ill cases at that moment. Conversely, mild patients did not need plasma. Second, the amounts of viral antibodies given to each patient was unknown and not standardized, which may lead to different clinical outcomes. Nevertheless, all plasma receiving patients underwent viral clearance after transfusions. Third, it was not randomized. However, the limited plasma availability, timeliness, ABO compatibility resulted in almost only one suitable patient existed at each certain circumstance. Last, the SARS-CoV-2 RNA was not quantitated because of the technic limitation of testing. In conclusion, the current study firstly suggests that convalescent plasma therapy can discontinue the viral shedding and contribute longer survival duration in COVID-19 patients with respiratory failure, although it cannot reduce the mortality in critically end-stage patients. Additionally, we suggest that convalescent plasma treatment should be infused for potentially critical COVD-19 patients at their early phase based on the current study. What to do next to control the 2019-nCoV epidemic? A novel coronavirus outbreak of global health. concern World Health Organization. Coronavirus disease (COVID-19) Situation Report -94 Clinical Characteristics of. Coronavirus Disease 2019 in China First Case of Novel Coronavirus in the United States A Trial of Lopinavir-Ritonavir in. Adults Hospitalized with Severe Covid-19 Retrospective comparison. of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients Use of convalescent. plasma therapy in SARS patients in Hong Kong Convalescent plasma as a potential therapy for COVID-19 Convalescent plasma. treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection Clinical management of severe acute respiratory infection. when novel coronavirus (nCoV) infection is suspected Sex-Based. Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection Clinical course and risk factors for. mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Coronavirus disease (COVID-19) Situation Report -55 Clinical progression. and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study